Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
New Horizon Health Ltd
6606New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2015 and is headquartered in Hangzhou, China. Address: T1 Building, Hangzhou, China, 310052
Analytics
WallStreetin tavoitehinta
359.54 HKDP/E-suhde
58.9167Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut 6606
Osinkoanalytiikka 6606
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria 6606
Osakkeen arvostus 6606
Talousasiat 6606
Tuloksia | 2019 | Dynamiikka |